Evidence map›Paper›PMID 29552666›Full record

ArticleAmerican journal of ophthalmology case reports2018

Improvement of chronic corneal opacity in ocular surface disease with prosthetic replacement of the ocular surface ecosystem (PROSE) treatment.

Anna Cressey, Deborah S Jacobs, Crystal Remington, Karen G Carrasquillo

Open access · goldAbstract readCase Reports
In one paragraph

Article in American journal of ophthalmology case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Two cases of therapeutic scleral lenses for KID syndrome.American journal of ophthalmology case reports · 2025
    Article
  3. Scleral lenses and PROSE: indications, complications, and future challenges.Medical hypothesis, discovery & innovation ophthalmology journal · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Familial dysautonomia.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2023
    Review
  8. Article
  9. Article
  10. Advances in dry eye disease treatment.Current opinion in ophthalmology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Anna CresseyBostonSight, 464 Hillside Ave, Suite 205, Needham, MA, 02494, United States.
Deborah S JacobsBostonSight, 464 Hillside Ave, Suite 205, Needham, MA, 02494, United States.
Crystal RemingtonBostonSight, 464 Hillside Ave, Suite 205, Needham, MA, 02494, United States.
Karen G CarrasquilloBostonSight, 464 Hillside Ave, Suite 205, Needham, MA, 02494, United States.
Boston Foundation · USNew England College of Optometry · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo demonstrate clearing of chronic corneal opacities and improvement of visual acuity with the use of BostonSight prosthetic replacement of the ocular surface ecosystem (PROSE) treatment in ocular surface disease. OBSERVATIONS: We undertook retrospective analysis of the medical records of a series of patients who underwent PROSE treatment from August 2006 to December 2014. Patients were referred for ocular surface disease of various etiologies. Primary inclusion criterion was corneal opacity that improved with PROSE treatment. Patients were excluded if topical steroids or adjuvant therapy used once PROSE treatment was initiated. Underlying disease, prior treatment, clinical presentation, and clinical course were extracted from the medical record. Four patients are included in this series. There were three females and one male; median age at time of treatment initiation was 30 years (range = 0.5-58 years). Median duration of PROSE treatment at time of retrospective analysis was 3.5 years (range = 1-8 years). Two cases had corneal opacification in the context of neurotrophic keratopathy: a unilateral case due to presumed herpes simplex keratitis and a bilateral case due to congenital corneal anesthesia associated with familial dysautonomia. One case had corneal opacity from exposure related to seventh nerve palsy, and one had corneal opacification associated with recurrent surface breakdown, neurotrophic keratopathy, and limbal stem deficiency of uncertain etiology. After consistent wear of prosthetic devices used in PROSE treatment for support of the ocular surface, visual acuity improved and clearing of the opacities was observed, without use of topical steroids or adjuvant therapy. CONCLUSIONS AND IMPORTANCE: These cases demonstrate clearing of chronic corneal opacity with PROSE treatment for ocular surface disease. This clearing can occur with no adjuvant therapy, suggesting that restoration of ocular surface function and integrity allows for corneal remodeling.

Indexed as

Corneal scarDry eye syndromeOcular surface diseaseOpacityPROSE treatmentScleral lensesScleral prosthetic devices

Identifiers

PMID29552666
PMCPMC5852325
OpenAlexW2790902268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.